CSBio CSBio

X
[{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Eisai","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy\u2019s Laboratories Presents Preclinical Data at SITC 2020 Demonstrating Significant Improvement in Tumor Growth Inhibition and Overall Survival Through a Combination of E7777 (Denileukin Diftitox) and an Immune Checkpoint Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"INDIA","productType":"Large molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Dr. Reddy\\'s Laboratories"},{"orgOrder":0,"company":"Aurigene","sponsor":"Exelixis","pharmaFlowCategory":"D","amount":"$29.5 million","upfrontCash":"$10.0 million","newsHeadline":"Exelixis In-Licenses Aurigene\u2019s CDK7 Inhibitor and Files Investigational New Drug Application for Phase 1 Trial in Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"INDIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Aurigene"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Lupin Announces Achievement of Key Milestones for its Clinical Stage MEK Inhibitor Compound","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"INDIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Lupin Ltd"},{"orgOrder":0,"company":"NovoMedix","sponsor":"National Heart, Lung, and Blood Institute","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"NovoMedix Receives Research Grant from the National Institutes of Health (NIH) to Advance NMX1 in TBNC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"INDIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"NovoMedix"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Combination of E7777 with an anti-PD-1 agent provided clear benefit both in terms of tumor growth control, and a highly significant improvement in overall survival.

            Lead Product(s): Denileukin Diftitox,Anti-PD-1 agent

            Therapeutic Area: Oncology Product Name: E7777

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Eisai

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 09, 2020

            Details:

            The SBIR grant will support the development of NMX1 and novel small molecules that protect Triple-Negative Breast Cancer (TNBC) patients from the devastating long-term cardiotoxic effects of doxorubicin chemotherapy.

            Lead Product(s): NMX1

            Therapeutic Area: Oncology Product Name: NMX1

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: National Heart, Lung, and Blood Institute

            Deal Size: $2.0 million Upfront Cash: Undisclosed

            Deal Type: Funding May 26, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Lupin’s proprietary MEK inhibitor compound is planned for clinical development in combination with Boehringer Ingelheim’s KRAS inhibitor pipeline to address KRAS-driven cancers.

            Lead Product(s): LNP3794,BI 1701963

            Therapeutic Area: Oncology Product Name: BI 3011441

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH

            Deal Size: $50.0 million Upfront Cash: Undisclosed

            Deal Type: Collaboration May 27, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Exelixis has exercised exclusive option for Aurigene’s novel CDK7 inhibitor under the companies’ July 2019 agreement. Exelixis has now assumed responsibility for the future clinical development, commercialization, and global manufacturing of the compound now known as XL102.

            Lead Product(s): XL102

            Therapeutic Area: Oncology Product Name: XL102

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Exelixis

            Deal Size: $29.5 million Upfront Cash: $10.0 million

            Deal Type: Licensing Agreement December 07, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY